Chronic Kidney Diseases
701
136
170
316
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Published Results
60 trials with published results (9%)
Research Maturity
316 completed trials (45% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
4.3%
30 terminated out of 701 trials
91.3%
+4.8% vs benchmark
10%
73 trials in Phase 3/4
19%
60 of 316 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 316 completed trials
Clinical Trials (701)
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score
Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease
Bone in CKD Alkali Response (BICARb Pilot Trial)
Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml/Min/1.73m2
Sit Less, Interact and Move More (SLIMM) 2 Study
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
Enhancing Physical Function in Older Adults With Chronic Kidney Disease
NAVIGATE Kidney: A Multi-level Intervention to Reduce Kidney Health Disparities
Designing and Implementing a Safety Net Surveillance Program for High Risk CKD
Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults With Chronic Conditions
Effect of 4-7-8 Breathing on AV Fistula Needle Pain in Dialysis Patients
4-7-8 Breathing for Fatigue and Sleep Management in Hemodialysis
Care Transitions App for Patients With Multiple Chronic Conditions
Dialysis Geriatric Care Model
Antibiotic Prophylaxis in High-Risk Arthroplasty Patients
System Interventions to Achieve Early and Equitable Transplants Study - Long-Term
Protecting Kidneys Through a Low Protein Diet: A Stepwise Multiple-Choice System Approach
Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension
Assessment of T-cell Response and In-vitro Proof-of-concept of T-cell Engineering in Chronic ESKD Patients.